Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This open-label, non-randomized Phase II trial is designed to assess the safety and
tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or
refractory, metastatic NSCLC. The study will consist of a safety lead-in of 10-20 patients. A
total of 50 patients will be treated with the combination at the safest dose of GT103 as
determined in the safety lead-in. If 10 additional patients are enrolled to the dose level -1
then the maximum of 60 subjects may be accrued to this trial.